GT
CAPR icon

Glenmede Trust’s Capricor Therapeutics CAPR Stock Holding History

Glenmede Trust’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$962K Buy
39,935
+3,605
+10% +$109K ﹤0.01% 780
2026
Q1 		$1.1M Buy
36,330
+4,240
+13% +$113K 0.01% 709
2025
Q4 		$926K Buy
+32,090
New +$419K ﹤0.01% 747

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Glenmede Trust's CAPR Position: Q2 2026 in Review

Glenmede Trust increased its Capricor Therapeutics (CAPR) stake by 9.9% in Q2 2026, buying an estimated $109K and bringing the position to 39,935 shares worth $962K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

Glenmede Trust first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.1M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Glenmede Trust held 39,935 shares of Capricor Therapeutics worth $962K as of Q2 2026.
  • Glenmede Trust bought 3,605 Capricor Therapeutics shares in Q2 2026, an estimated $109K.
  • Capricor Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #780 holding.
  • Glenmede Trust first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Glenmede Trust's Capricor Therapeutics position peaked at $1.1M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.